Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Science

International Symposium on Compound Design Technologies


Print article Print article

2014-02-10 12:06:59 - Guiding Better Decisions in Drug Discovery and Development
March 19th, 2014 at British Embassy in Tokyo
March 20th, 2014 at British Consulate-General in Osaka


Cambridge, UK – 6th February 2014 – Cresset, Optibrium, Lhasa Limited and Chemogenomix, innovative providers of computational chemistry software and services, announce the ‘International Symposium on Compound Design Technologies: Guiding Better Decisions in Compound Design Technologies’. The symposium will be held on March 19th at the British Embassy in Tokyo and on March 20th at the British Consulate-General in Osaka.
Of particular interest to computational chemists working in the pharmaceutical, biotechnology and drug discovery industries, attendees will hear about technologies that guide them to successful small molecule and biotherapeutic drug discovery and development, intuitive molecular design and 3D-QSAR interpretation as well as knowledge based toxicity prediction.
The keynote presentation will be made by Dr John Overington (EMBL-EBI) with other presentations from Dr.

Kimito Funatsu (University of Tokyo), Dr. Yoshio Hamada (Kobe Gakuin University) and Dr. Hiroshi Chuman (University of Tokushima), Dr. Matt Segall (Optibrium), Dr. Tim Cheeseright (Cresset), Dr. Thierry Hanser (Lhasa Limited) and Dr. Mark Swindells (Chemogenomix).
The full program, and free registration, is online at www.cresset-group.com/news-events/events/international-symposium ...


Author:
Sophie Woodward
e-mail
Web: www.kdm-communications.com
Phone: 01480405333

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com